Copper oxide nanoparticles (CuO NPs) were synthesized from the methanolic extract of Prunus amygdalus pericarp. The presence of Phytocompounds such as tetrahydroaraucarlone, Prostaglandin A2, Molybdenum complex, trienoic acid and other phenolic constituents in almond hulls act as a reducing agent to synthesize the CuO NPs from Cu (II) to Cu (0) and as a capping agent to stabilize the nanoparticles. The prepared CuO NPs were characterized by UV-Vis Spectrophotometer, Fourier Transform Infrared Spectroscopy (FTIR), Gas Chromatography-Mass Spectra (GCMS), X-ray Diffraction (XRD) and Scanning Electron Microscopy (SEM). The synthesized CuO NPs are crystalline with average size range 11–12 nm and this bioreduction green approach is more efficient to synthesize the controlled shape and size of CuO NPs for pharmaceuticals, optoelectronics and biotechnology purpose.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: